Bone Regeneration Company Sets Multiple Sales Record Marks Despite Challenging Market Conditions
IRVINE, Calif. — August 10, 2022 /OrthoSpineNews/ — Irvine-based Biogennix, a market leader in advanced bone regeneration technology, announced today that the second quarter of 2022 was the best in company history. The company also announced that the first half of 2022 (encompassing the first and second quarters of 2022) was the best performing six month period for the company to date.
“Thanks to a positive reception for our more recent offerings like the DirectCell Advanced Bone Grafting System and Agilon advanced synthetic bone graft products, in addition to continued strong sales of our legacy bone graft products, Biogennix is ahead of pace to once again achieve our best sales year in company history,” said Chris MacDuff, Biogennix’s CEO. “Both our DirectCell System and Agilon Moldable product lines have grown over 20% quarter over quarter this year, and sales have more than tripled for both when compared to the first half of 2021. It is rewarding to have achieved this sales growth during challenging market conditions.”
Biogennix continues to see particularly strong growth within the foot & ankle surgery market, especially with the DirectCell System and Agilon Moldable products. Both have rapidly gained popularity among surgical podiatrists who are drawn to the excellent handling and the cell-stimulating surface technology of Agilon, and the ability to harvest autologous stem cells without the need to centrifuge when using the DirectCell System. Biogennix also continues to achieve strong numbers in the spine and general orthopedic market segments, where the company has historically made the most impact.
Biogennix CTO, Mark Borden, Ph.D., alluded to future offerings, adding, “Expanding on Biogennix’s expertise in advanced bone graft technologies, we have established a strong development pipeline and are focused on launching a variety of innovative solutions. We are looking forward to further growth in the second half of this year and into 2023.”
Biogennix’s proprietary TrelCor technology is a bioactive synthetic material engineered to jumpstart patients’ natural healing processes at the cellular level. TrelCor technology uniquely combines multiple cutting-edge scientific principles into one advanced material that actively promotes cellular healing and new bone formation.
Biogennix designs, manufactures and distributes all of its products from its Irvine facilities.
Biogennix® is a market leader in advanced bone regeneration technologies. Biogennix is headquartered in Irvine, CA where they develop, manufacture, and distribute proprietary technologies used in bone fusion procedures. Biogennix team members are experts in bone graft science who are focused on creating solutions that keep distributors and surgeons on the forefront of bone regeneration. Learn more at biogennix.com.
Media Contact: Paul Williams, 310-569-0023,